securities fraud

Class action lawsuit filed against $LAKE alleging executives made false statements about Pacific Helmets and Jolly business performance while concealing operational challenges.

Class action lawsuit filed against FBRT alleging executives made false statements about dividend sustainability between November 2024 and February 2026.

Class action lawsuit filed against AMC Entertainment over APE dividend exclusion, alleging securities fraud and material misrepresentations regarding investor protections.

Rosen Law Firm investigates $HKIT for allegedly issuing materially misleading information, preparing potential class action lawsuit for affected investors.

Class action lawsuit filed against $PLUG alleging false statements about DOE funding and hydrogen facilities between January and November 2025. Investors can seek lead plaintiff status by April 3, 2026.

Class action filed against Aldeyra Therapeutics alleging false reproxalap trial data claims; investors from Nov 2023-Mar 2026 may be eligible.

Class action lawsuit filed against $BSX alleging materially false statements regarding U.S. electrophysiology segment growth projections and undisclosed adverse trends.

Class action filed against NASDAQ-listed CIGL for alleged stock promotion fraud involving fake social media accounts, impersonated advisors, and insider share dumping through offshore accounts.

The Portnoy Law Firm investigates $ICHR following a 23.2% stock collapse tied to Q1 2025 earnings miss and margin compression.

Schall Law Firm launches class action against Power Solutions International for allegedly misrepresenting data center market prospects and manufacturing costs between May 2025 and March 2026.

$PSIX sued for allegedly making false statements about data center business prospects and understating manufacturing upgrade costs between May 2025 and March 2026.

uniQure's stock plummeted 49% after FDA rejected its AMT-130 drug candidate; securities fraud lawsuit filed for alleged failure to disclose approval risks during September-October 2025.

Ultragenyx faces securities fraud lawsuit after setrusumab Phase 3 failure triggered 42% stock decline. Lead plaintiff applications due April 6, 2026.

ImmunityBio faces securities fraud lawsuit following FDA warning letter about Anktiva cancer therapy misleading ads. Stock plummeted to $7.42.

Trip.com faces securities fraud class action after China's antitrust regulator probes alleged monopolistic practices. Stock fell 19.4% in January 2026.

Law firm alleges Navan concealed 39% surge in sales-marketing spending to $95M in Q3 2025 during October IPO. Class action deadline set for April 24, 2026.

Law firm Kahn Swick & Foti files class action against $ENPH alleging financial misstatements; April 20, 2026 deadline for lead plaintiff applications.

Law firm launches class action against $KYD over alleged securities fraud, citing missed filings, control weaknesses, and executive departures following stock plunge.

Driven Brands ($DRVN) stock crashed 40% after disclosing material financial statement errors spanning 2023-2025, triggering securities fraud class action litigation.

Gartner faces securities class action after stock plunged 48% due to undisclosed contract value growth deterioration. Investors have until May 18, 2026, to file claims.